Artelinic acid has a lower rate of neurotoxicity than the related artemisinin derivatives arteether and artemether, but is three times more toxic than artesunate. At present, artelinic acid seems unlikely to enter routine clinical use, because it offers no clear benefits over the artemesinins already available (artesunate and artemether).
Artelinic acid's toxicity profile indicates a lower risk compared to its related compounds arteether and artemether, but it is three times more toxic than artesunate. As of now, artelinic acid seems unlikely to be used in routine clinical settings due to the lack of clear benefits over existing treatments (artesunate and artemether).